title: Nasal shedding of equine herpesvirus-1 from horses in an outbreak of equine herpes myeloencephalopathy in Western Canada.
abstract: BACKGROUND
  There is little information on the duration of nasal shedding of EHV-1 from horses with naturally occurring equine herpesvirus myeloencephalopathy (EHM).
  
  
  OBJECTIVE
  To evaluate the duration of nasal shedding of EHV-1 in horses affected by EHM.
  
  
  METHODS
  One hundred and four horses naturally exposed to EHV-1, 20 of which had clinical signs of EHM.
  
  
  METHODS
  All horses on affected premises were monitored. Those horses developing EHM were sampled in a longitudinal outbreak investigation. Nasal swabs were collected daily from 16 of 20 horses affected by EHM. A qPCR was performed on 98 of 246 nasal swab samples to determine nasal shedding duration. Historical and clinical information was analyzed to evaluate potential risk factors for developing EHM and duration of shedding during this outbreak.
  
  
  RESULTS
  The last day shedding was detected in any horse was Disease Day 9. EHV-1 was detected in two-thirds of horses tested on Disease Days 0-3. The amount of EHV-1 DNA found in nasal swabs varied markedly and was not associated with disease severity or age. The odds of developing EHM were greater for febrile horses (OR = 20.3; 95% CI 3.4-390.3; P = .01) as well as for horses attending the riding clinic (OR = 4.1; 95% CI 0.84-21.65; P = .08).
  
  
  CONCLUSIONS
  Biosecurity measures should be implemented for a minimum of 14 days beyond the onset of clinical signs of EHM. Animal managers cannot rely on the severity of clinical signs to predict the duration of EHV-1 shedding.
authors.affiliation: Department of Large Animal Clinical Sciences, University of Saskatchewan, Saskatoon, SK, Canada.
authors.forename: B A
authors.initials: BA
authors.lastname: Burgess
authors.forename: N
authors.initials: N
authors.lastname: Tokateloff
authors.forename: S
authors.initials: S
authors.lastname: Manning
authors.forename: K
authors.initials: K
authors.lastname: Lohmann
authors.forename: D P
authors.initials: DP
authors.lastname: Lunn
authors.forename: S B
authors.initials: SB
authors.lastname: Hussey
authors.forename: P S
authors.initials: PS
authors.lastname: Morley
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics; D004196:Disease Outbreaks / Q000662:veterinary*; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D006566:Herpesviridae Infections / Q000453:epidemiology / Q000276:immunology / Q000662:veterinary* / Q000821:virology; D004861:Herpesvirus 1, Equid / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D006734:Horse Diseases / Q000453:epidemiology / Q000276:immunology / Q000821:virology*; D006736:Horses; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D009297:Nasal Mucosa / Q000276:immunology / Q000821:virology; D009422:Nervous System Diseases / Q000453:epidemiology / Q000276:immunology / Q000662:veterinary* / Q000821:virology; D016133:Polymerase Chain Reaction / Q000662:veterinary; D012525:Saskatchewan / Q000453:epidemiology; D017201:Virus Shedding / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral